​

Cullinan Therapeutics (CGEM) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

CGEM Stock Forecast

Cullinan Therapeutics (CGEM) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $31.00, with a high of $37.00 and a low of $28.00. This represents a 138.83% increase from the last price of $12.98.

$10 $16 $22 $28 $34 $40 High: $37 Avg: $31 Low: $28 Last Closed Price: $12.98

CGEM Stock Rating

Cullinan Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 8 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 8 Strong Sell Sell Hold Buy Strong Buy

CGEM Price Target Upside V Benchmarks

TypeNameUpside
StockCullinan Therapeutics138.83%
SectorHealthcare Stocks 15.45%

Price Target Trends

1M3M12M
# Anlaysts-210
Avg Price Target-$33.50$31.60
Last Closing Price$12.98$12.98$12.98
Upside/Downside-158.09%143.45%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 26111---12
May, 26111---12
Apr, 26111---12
Mar, 26111---12
Feb, 26110---11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
May 08, 2026Wedbush$37.00$14.76150.68%185.05%
Apr 28, 2026Robert BurnsH.C. Wainwright$30.00$12.79134.56%131.12%
Mar 11, 2026Wedbush$36.00$14.31151.57%177.35%
Mar 10, 2026Alex ThompsonStifel Nicolaus$28.00$15.1185.31%115.72%
Feb 02, 2026Guggenheim$30.00$11.96150.84%131.12%
Jan 08, 2026H.C. Wainwright$27.00$10.77150.70%108.01%
Jan 08, 2026Morgan Stanley$30.00$10.94174.22%131.12%
Dec 09, 2025Robert DriscollWedbush$34.00$12.18179.15%161.94%
Nov 24, 2025Julian HarrisonBTIG$38.00$11.90219.33%192.76%
Nov 20, 2025New Street$26.00$8.92191.48%100.31%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jun 10, 2026William BlairOutperformOutperformhold
May 08, 2026WedbushOutperformOutperformhold
Apr 28, 2026H.C. WainwrightBuyBuyhold
Feb 17, 2026CitigroupBuyinitialise
Feb 02, 2026GuggenheimBuyinitialise
Jan 08, 2026H.C. WainwrightBuyBuyhold
Jan 08, 2026Morgan StanleyOverweightOverweighthold
Dec 17, 2025Cowen & Co.BuyBuyhold
Dec 09, 2025WedbushOutperformOutperformhold
Nov 24, 2025BTIGBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.48$-3.69$-3.11----
Avg Forecast$-1.28$-4.09$-3.04$-3.10$-3.00$-2.33$-2.87
High Forecast$-0.89$-4.05$-2.95$-2.51$-2.42$-0.05$-1.60
Low Forecast$-1.67$-4.13$-3.33$-4.09$-4.65$-4.12$-4.14
Surprise %15.63%-9.78%2.30%----

Revenue Forecast

$0 $16M $32M $48M $64M $80M Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$18.94M------
Avg Forecast$18.91M-$1.67M$10.65M$33.02M$56.13M$58.02M
High Forecast$23.38M-$2.24M$14.28M$33.16M$56.64M$77.82M
Low Forecast$14.46M-$1.10M$7.02M$32.89M$55.62M$38.24M
Surprise %0.15%------

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 21 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.57M$-153.16M$-167.38M$-219.88M---
Avg Forecast$-53.08M$-169.76M$-130.49M$-137.20M$-146.98M$-86.74M$-119.11M
High Forecast$-36.82M$-168.11M$-122.60M$-104.43M$-100.70M$-2.28M$-66.31M
Low Forecast$-69.35M$-171.42M$-138.38M$-169.96M$-193.27M$-171.21M$-171.96M
Surprise %23.53%-9.78%28.28%60.27%---

CGEM Forecast FAQ

Is Cullinan Therapeutics stock a buy?

Cullinan Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 8 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Cullinan Therapeutics is a favorable investment for most analysts.

What is Cullinan Therapeutics's price target?

Cullinan Therapeutics's price target, set by 8 Wall Street analysts, averages $31 over the next 12 months. The price target range spans from $28 at the low end to $37 at the high end, suggesting a potential 138.83% change from the previous closing price of $12.98.

How does Cullinan Therapeutics stock forecast compare to its benchmarks?

Cullinan Therapeutics's stock forecast shows a 138.83% upside, outperforming the average forecast for the healthcare stocks sector (15.45%).

What is the breakdown of analyst ratings for Cullinan Therapeutics over the past three months?

  • June 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • May 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 8.33% Strong Buy, 91.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Cullinan Therapeutics’s EPS forecast?

Cullinan Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-3, marking a 0% decrease from the reported $0 in 2025. Estimates for the following years are $-2.33 in 2027, and $-2.87 in 2028.

What is Cullinan Therapeutics’s revenue forecast?

Cullinan Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $33.02M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $56.13M, and $58.02M for 2028.

What is Cullinan Therapeutics’s net income forecast?

Cullinan Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-147M, representing a -33.15% decrease from the reported $-220M in 2025. Projections indicate $-86.744M in 2027, and $-119M in 2028.